56 results about "Mesoderm Cell" patented technology

The present invention provides compositions and methods for the production of differentiated mammalian cells. More particularly, the present invention provides cellular differentiation methods employing culturing the cells on a feeder layer or under feeder-free conditions in cell culture and further contacting the cells with an inhibitor of the PI3-kinase pathway for the generation of differentiated mammalian cells from pluripotent mammalian stem cells. Preferably, the differentiated cell is selected from the group consisting of a mesendodermal cell, a mesodermal cell, and an endodermal cell.

The present invention relates generally to the generation of cells of mesodermal lineage. More particularly, the present invention contemplates a method for the preparation of differentiated or partially differentiated mesodermal cells and their use in tissue repair, regeneration and / or augmentation therapy. The identification and generation of the mesodermal cells further provides a source of transcriptome or proteome data to assess the expression profile of genes associated with the maintenance of mesodermal cells as well as their differentiation, proliferation, expansion and / or renewal potential.

The invention provides an inducing medium for inducing multipotential stem cells to form mesoblastic cells. The inducing medium is prepared from the following components with the corresponding concentrations: 5-15 mM of LiCl, 0.5-2 % of glutamine, 0.5-2 % of non-essential amino acid, 5-15 [mu] M of CHIR99021, 8-15 ng / ml of bFGF, 0.05-0.2 mmol / l of beta mercaptoethanol, 0.2-0.6 [mu] g / ml of hydrocortisone, 4-10 [mu] g / ml of insulin, 80-120 [mu] g / ml of transferrin, 8-12 ng / ml of sodium selenite, 0.05-0.2 mg / ml of penicillin, and 0.05-0.2 mg / ml of streptomycin. For the inducing medium, on the basis of the DMEM / F12 culture medium, some specific cytokines and supplements are added, and thus the probability of inducing the multipotential stem cells to differentiate towards the mesoblastic cells is improved. In addition, the invention provides an inducing method for inducing the multipotential stem cells to form the mesoblastic cells, according to the method, the simple embryoid body for inducing the multipotential stem cells is inoculated to the inducing medium for induced culture, and thus the multipotential stem cells efficiently differentiate to form the mesoblastic cells.

Methods for obtaining multipotent Apelin receptor-positive lateral plate mesoderm cells, mesenchymal stem cells, and mesangioblasts under serum-free conditions are disclosed

The invention relates to a method to induce primate embryonic stem cells to differentiate into a relatively homogenous population of mesoendoderm cells by treatment with caspase-like inhibitors. Also described is a population of mesoendoderm cells obtained therefrom. The embryonic stem cell derived mesoendoderm cells have the general morphological and cell surface marker characteristics of mesoendoderm cells.

The invention provides a method for differentiating as ventricular muscle cells by in-vitro induced pluripotent stem cells. The method comprises the following steps: through maintaining, amplifying, and culturing pluripotent stem cells in vitro, in the metaphase of pluripotent stem cell cardiac muscle differentiation, namely the differentiation stage from mesoblastema or cardiac muscle precursor cells to the cardiac muscle cells, adding a substance for directly or indirectly activating an Smad1 / 5 / 8 signal channel to a culture medium, and enabling the stem cells to be directionally differentiated as the ventricular muscle cells. The ventricular muscle cells with the biology activity and function can be successfully obtained by using the method. A regulation mechanism in the differentiation process from the cardiac muscle precursor cells to the ventricular muscle cells is presented, and the human ventricular muscle cells obtained by the differentiation can be extensively applied for the myocardial infarction therapy by the cell transplantation and the cardiac toxicology analysis and the development of cardiac related drugs.

The invention discloses a method for realizing efficient differentiation of induced pluripotent stem cells towards mature endothelial cells, belonging to the technical field of cell engineering. The method comprises the following steps: carrying out pretreatment culturing on the induced pluripotent stem cells; carrying out induction to form side plate mesoblastic cells; carrying out inducing to form endothelial progenitor cells tending to the endothelial cells; and carrying out inducing to form the mature endothelial cells. According to the method, various cell inducing factors are matched through increase and decrease, meanwhile, the reasonable upgrading is carried out on the inducing method, thus the directional differentiation of the induced pluripotent stem cells towards the endothelial cells can be efficiently induced, under the condition that a small number of induced pluripotent stem cells are adopted and the purifying operation is not needed, a large number of mature endothelial cells with high purity and complete functions are obtained.

A tissue structure for enabling comprehensive understanding of gene patterns of mature cells and a method of preparing the tissue structure are provided. A tissue structure is obtained by co-culturing an endodermal, ectodermal, or mesodermal cell derived from a stem cell and at least one cell and / or factor selected from the group consisting of a vascular cell, a mesenchymal cell, a factor secreted by a vascular cell, a factor secreted by a mesenchymal cell, and a factor secreted when both a vascular cell and a mesenchymal cell exist. A value obtained by assay of a plurality of functions using a Pearson product-moment correlation coefficient is closer to a value of a cell or biological tissue sampled from an adult than a value of a cell or biological tissue sampled from a fetus.

Provided is a method of producing a skeletal muscle progenitor cell using a pluripotent stem cell, particularly an iPS cell, the method comprising the step 1) of culturing a pluripotent stem cell under serum-free conditions, and in the presence of Activin A, to allow the cell to differentiate into a PDGFRα-positive mesodermal cell, and the step 2) of culturing the mesodermal cell under serum-free conditions, and in the presence of a Wnt signal inducer, to allow the cell to differentiate into a skeletal muscle progenitor cell. Also provided are a cell population containing a skeletal muscle progenitor cell as obtained by the method, and a skeletal muscle regeneration promoting agent and therapeutic agent for muscular diseases such as muscular dystrophy, the promoting agent or agent comprising the skeletal muscle progenitor cell as an active ingredient.

The present invention provides a method for inducing differentiation of pluripotent stem cells into mesodermal cells, comprising the step of culturing pluripotent stem cells in a serum-free medium without forming an embryoid body and without coculturing with cells from a different species.

A method for producing renal progenitor cells from pluripotent stem cells, comprising steps (i) to (vi): (i) culturing the pluripotent stem cells in a culture medium containing FGF2, BMP4, a GSK-3[beta] inhibitor and retinoic acid or a derivative thereof; (ii) culturing cells produced in step (i) in a culture medium containing FGF2, a GSK-3[beta] inhibitor and BMP7; (iii) culturing cells producedin step (ii) in a culture medium containing FGF2, a GSK-3[beta] inhibitor, BMP7 and a TGF[beta] inhibitor; (iv) culturing cells produced in step (iii) in a culture medium containing FGF2, a GSK-3[beta] inhibitor, BMP7, activin and a ROCK (Rho-kinase) inhibitor; (v) culturing cells produced in step (iv) in a culture medium containing retinoic acid or a derivative thereof and FGF9; and (vi) culturing cells produced in step (v) in a culture medium containing a GSK-3[beta] inhibitor and FGF9 to induce renal progenitor cells from intermediate mesodermal cells.

This invention relates to a method for producing cardiomyocytes and / or cardiac progenitor cells, comprising culturing an induced pluripotent stem (iPS) cell or embryonic stem (ES) cell, which has been differentiated into a mesoderm cell, in the presence of cyclosporin-A.

The invention provides a method of using multipotent stem cells to prepare epicardial cells, comprising: 1) inducing multipotent stem cells to differentiate into mesodermal cells by activating a WNT signal pathway; 2) converting the mesodermal cells in step 1) into myocardial precursor cells by inhibiting the WNT signal pathway; 3) converting the myocardial precursor cells in step 2) into preliminary epicardial cells by activating a fibroblast growth factor signal pathway and the WNT signal pathway; preparing pericardial cells with the preliminary epicardial cells of step 3). The invention also relates to: a method of using multipotent stem cells to prepare vascular smooth muscle cells and cardiac fibroblasts; epicardial cells, vascular smooth muscle cells and cardiac fibroblasts all of which are prepared through the above method; and their application.

The invention discloses a method for preparing heart valve endothelial cells by inducing differentiation of pluripotent stem cells, and application of the heart valve endothelial cells. The method comprises the following steps: planting pluripotent stem cells in a culture dish coated with matrix glue in a tiled manner, and culturing the pluripotent stem cells by using Essential 8 to enable the pluripotent stem cells to be attached to the wall of the culture dish; and culturing the pluripotent stem cells in a differential medium Essential 6 containing Wnt3a and bone morphogenetic protein 4, culturing the pluripotent stem cells in a differential medium Essential 6 containing epidermal growth factors and bone morphogenetic protein 4, digesting mesoderm cells of the heart, and putting the cardiac mesoderm cells in the culture dish into a differential medium Essential 6 containing bone morphogenetic protein 4, transforming growth factors and endothelial growth factors for continuous cultureto obtain heart valve endothelial cells. The method disclosed by the invention is high in differentiation efficiency, and more than 80% of valvular endothelial cells can be obtained under the condition that flow sorting is not carried out, so that sufficient seed cell sources can be guaranteed.

This invention provides pertains to the discovery that that nicotine interrupts molecular signaling between endodermal and mesodermal cells of the lung alveolus. Treatment of the lung with specific molecular agents (e.g., PPAR gamma agonists) can prevent and / or reverse the injury caused by nicotine.

The invention provides a method for inducing and differentiating human embryonic stem cells (hESCs) into mesenchymal stem cells (MSCs). The method mainly relates to three stages, including induction of primitive streak (PS) cells, differentiation to outer mesoderm cells and differentiation of the MSCs. According to the method, a staged differentiation method is adopted, the whole differentiation process can be tracked and subjected to quality control, the cost is low, and operation is easy. An intermediate product of hESCs induced and differentiated into MSCs is obtained and comprises PS cells, outer mesoderm cells and MSCs, more MSCs can be efficiently generated, the multiplication time is shorter, the MSCs can be repeated, and mature MSCs can be obtained in 17 days at the shortest time,wherein the differentiation induction culture media in the first two stages are serum-free culture media with clear components, so that differentiated MSCs are prevented from being polluted by exogenous substances, and the uniformity and clinical applicability of the differentiated MSCs are guaranteed.

The present invention provides a method for inducing pluripotent stem cells to differentiate into ventricular myocytes in vitro, which is to maintain, amplify, and cultivate pluripotent stem cells in vitro, and in the middle stage of myocardial differentiation of pluripotent stem cells, the mesoderm cells or myocardial precursor cells develop into In the period of cardiomyocyte differentiation, substances that can directly or indirectly activate the Smad1 / 5 / 8 signaling pathway are added to the medium to make the stem cells differentiate into ventricular myocytes. Utilizing the method of the present invention, ventricular myocytes with biological activity and function have been successfully obtained, which not only reveals the regulatory mechanism in the differentiation process of myocardial precursor cells into ventricular myocytes, but also differentiates human ventricular myocytes to cell transplantation for the treatment of myocardium. Infarction and cardiac toxicology analysis and the development of cardiac-related drugs have a wide range of applications.

The invention provides a method for purifying pluripotent vascular progenitor cells from a perinatal tissue. The method comprises the steps of pretreatment and acquisition, wherein in the acquisitionstep, immunomagnetic beads of two different ligands are used for marking and purifying the perinatal tissue cells, the first immunomagnetic beads are used for marking firstly, through positive expression, non-pluripotent vascular progenitor cells are recognized, and impurity cells are removed to obtain a high-concentration cell population containing the pluripotent vascular progenitor cells, thenthe impurity-removed perinatal tissue cells are marked through the second immunomagnetic beads, and recognition is carried out through positive expression to obtain the pluripotent vascular progenitorcells. The pluripotent vascular progenitor cells prepared through the method have phenotypes similar to phenotypes of bone marrow mesenchymal stem cells and perivascular cells at the same time, havethe same mesoderm cell differentiation function as the bone marrow mesenchymal stem cells, further have the functions of differentiating into mature vascular cells and promoting cardiovascular systemrepair and regeneration, and can maintain the cell morphology and the amplification capability.

The invention relates to a method for reprogramming target cells to multipotent progenitor cells capable of differentiating into muscular, skeletal or dermal cell lines. In particular, the invention relates to an ex vivo method for preparing induced presomitic mesoderm (iPSM) cells, said method comprising the steps of: a) providing target cells to be reprogrammed, and, b) culturing said target cells under appropriate conditions for reprogramming said target cells into iPSM cells, wherein said appropriate conditions comprises increasing expression of at least one T-Box transcription factor in said target cells. The invention further relates to the use of said iPSM cells, for example, for regenerating skeletal, muscle, dermal and cartilage tissues.

The invention relates to the field of biological medicine, in particular to a blood retinal outer barrier model, a construction method thereof and a culture medium combination adopted for constructingthe model. The invention provides a construction method of a scaffold-free material integrated oBRB model differentiated from human iPSC. The preparation method comprises the following main steps offirstly, inducing embryoid mesoderm cell spheres from iPSC in a 3D culture manner, then embedding the cell spheres into collagen I, and inducing the collagen I to form a vascular network sheet. And inoculating the RPE cells from the iPSC to the vascular network sheet, and co-culturing for a period of time to form an integral structure. The iPSC differentiation technology and the tissue engineeringtechnology are combined, the blood-retinal outer barrier structure is better simulated, a new research way for obtaining the oBRB model is provided, and a new replacement way is provided for stem cell treatment of AMD and other diseases.

The present invention relates to a method for producing endothelial cells, in which a step (a) of inducing a mesoblastic cell mass containing endothelial progenitor cells from pluripotent stem cells without forming embryoid bodies and a step (b) of culturing the mesoblastic cell mass containing the endothelial progenitor cells in the presence of RepSox are carried out in this order. According to the present invention, it becomes possible to produce high-quality endothelial cells from pluripotent stem cells with high efficiency. The endothelial cells produced by the method of the present invention are useful, for example, for the production of a myocardial cell sheet, and is expected to be used for the treatment of heart diseases. A myocardial cell sheet can be produced by mixing endothelial cells produced by the method of the present invention with myocardial cells and wall cells and then culturing the mixture.

The present invention relates to a method of generating neural stem cells from mesodermal cells. The invention further provides a cell population which has neural stem cell-like characteristics. The neural stem cells prepared according to the invention are useful in the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

The invention discloses a method for realizing efficient differentiation of induced pluripotent stem cells towards mature endothelial cells, belonging to the technical field of cell engineering. The method comprises the following steps: carrying out pretreatment culturing on the induced pluripotent stem cells; carrying out induction to form side plate mesoblastic cells; carrying out inducing to form endothelial progenitor cells tending to the endothelial cells; and carrying out inducing to form the mature endothelial cells. According to the method, various cell inducing factors are matched through increase and decrease, meanwhile, the reasonable upgrading is carried out on the inducing method, thus the directional differentiation of the induced pluripotent stem cells towards the endothelial cells can be efficiently induced, under the condition that a small number of induced pluripotent stem cells are adopted and the purifying operation is not needed, a large number of mature endothelial cells with high purity and complete functions are obtained.

The invention relates to a method for induced differentiation of human embryonic stem cells into NK cells, and belongs to the technical field of genetic engineering. The method comprises the following steps: resuscitation and passage of human embryonic stem cells, induction to obtain mesoderm cells, induction to obtain CD34 + hematopoietic stem cells, separation and purification of the CD34 + hematopoietic stem cells, induction to obtain NK cells, and multiplication culture. The human embryonic stem cells are human embryonic stem cell lines H9; the recovery and passage of the human embryonic stem cells are as follows: the human embryonic stem cells are recovered and then subjected to passage to the second generation, and when the cell confluence degree is more than 80%, mesoderm cells are obtained through induction; the NK cells are obtained through induced differentiation of human embryonic stem cells, and when the effect-target ratio is 20: 1, the killing rate of HELA tumor cell lines is 94.25%, and the killing rate of LOVO tumor cell lines is 91.24%.

An object of the present application is to provide a method for inducing the differentiation from pluripotent stem cells, particularly iPS cells and ES cells, into ureteric bud cells. Another object of the present application is to provide a system for producing ureteric bud-like tissue from pluripotent stem cells through each stage of differentiations, i.e. anterior primitive streak cells, anterior intermediate mesoderm cells and Wolffian duct cells. Yet another object of the present application is to provide a method for maintaining ureteric bud-like organoids. Another object of the present application is to provide a method for expansion-culturing ureteric bud-like tip tissue.